Emcutix and WiQo Sign Exclusive Licensing Partnership to Revolutionize Derma-cosmetic Treatments in India

Emcutix Biopharmaceuticals Limited, a wholly owned subsidiary of Emcure Pharmaceuticals Limited, announced an exclusive in-licensing agreement with WiQo, an innovative Italian derma-cosmetic and medical device company specialised in scientifically validated products. The strategic partnership grants Emcutix the rights to import, promote, distribute and sell WiQo's groundbreaking product PRX-PLUS in India. The collaboration is set to redefine the landscape of non-invasive skin treatments in the region.

PRX-PLUS has a unique product feature with its deep-impacting formula that instantly tightens the skin, offering a non-invasive, pain-free alternative to traditional aesthetic treatments for those seeking effective results with convenience.

Over 40,000 dermatologists and aesthetic doctors worldwide use WiQo's patented formulas. Since 2011 over 8 million needle-free skin booster professional procedures have been performed globally.

PRX-PLUS is an innovative combination. It features a cutting-edge droplet-based skincare solution that promotes immediate skin lifting without the use of injections, recovery time, or discomfort. It is safe for all skin types and phototypes and suitable for use in all seasons.

Sathya Narayanan, CEO - Emcutix Biopharmaceuticals Ltd. commented, "At Emcutix Biopharmaceuticals, our vision is to bring innovative and high-quality dermatology solutions to the Indian market. Our collaboration with WiQo marks a significant step toward fulfilling this commitment, introducing PRX-PLUS, a unique and advanced skincare solution. With the strong marketing expertise of Emcutix, we are confident that PRX-PLUS will set new benchmarks in dermatological care, making cutting-edge skincare more accessible to consumers across India."

Cristian Dufeu, WiQo CEO - commented "Partnering with Emcutix in India marks a significant milestone in our mission to revolutionize aesthetic treatments. With PRX Plus, we are not only introducing an innovative, needle-free solution for skin tightening, but also empowering dermatologists and patients with a safer, more effective alternative in the ever-evolving world of aesthetic medicine. This collaboration is a testament to our commitment to bringing ground-breaking, science-backed innovations to new markets, and we are excited to see the profound impact PRX-PLUS will have in India's dermatology landscape."

The dermatology market in India has been seeing consistent and significant growth in the last few years, owing to increasing awareness about skincare fuelled by growing disposable incomes. According to Indian Pharmaceutical Market (IPM) data*, the dermatology market size is estimated to be around 1.8 Billion USD, with a potential growth rate of 11-12% in the near future. This partnership underscores Emcutix's dedication to developing and introducing both prescription and consumer dermatology solutions across the country.

Shares of Emcure Pharmaceuticals Limited was last trading in BSE at Rs. 1072.80 as compared to the previous close of Rs. 1046.15. The total number of shares traded during the day was 3274 in over 472 trades.

The stock hit an intraday high of Rs. 1081.95 and intraday low of 1045.00. The net turnover during the day was Rs. 3507675.00.

Source : Equity Bulls

Keywords

EmcurePharmaceuticals INE168P01015 EmcutixBiopharmaceuticals InLicensingAgreement WiQO Italy DemraCosmeticTreatments India